Dr Reddy's Receives EIR for Formulations Manufacturing Unit in Andhra Pradesh
Key Highlights :
Dr Reddy's on Friday announced that it has received an establishment inspection report (EIR) for its formulations manufacturing unit in Srikakulam (FTO SEZ PU2), Andhra Pradesh. The EIR signals the closure of the inspection which was conducted from June 12, 2023 to June 16, 2023.
The US Food & Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed", the company said in a statement to stock exchanges. This successful clearance of the GMP inspection will enable Dr Reddy's to launch new products and mitigate the impact of pricing.
The news comes a day after the company's active pharmaceutical ingredient (API) manufacturing facility in Bollaram, Hyderabad (CTO-3), completed its USFDA's GMP (good manufacturing practices) inspection with zero observations.
The EIR for the Srikakulam facility is a major milestone for the company as it will help them to expand their production and launch new products in the market. The company is aiming to strengthen its presence in the domestic market and the new facility in Andhra Pradesh will help them to achieve their goals.
Dr Reddy's is one of the leading pharmaceutical companies in India and is known for its high-quality and affordable medicines. The company has a presence in over 40 countries and has been providing healthcare solutions to millions of people around the world.
The company has been investing in new technologies and expanding its production facilities in order to meet the growing demand for medicines. The new facility in Andhra Pradesh will help them to produce more medicines and make them available to the public at an affordable price.
The company has also been focusing on research and development and has been investing heavily in new technologies. This will help them to develop new medicines and treatments that can help people lead healthier and happier lives.
Dr Reddy's is committed to providing quality healthcare solutions to people around the world and the new facility in Andhra Pradesh will help them to achieve this goal. The successful clearance of the GMP inspection will help the company to grow and expand its operations in the future.
